Medmix Aktie
| 13,42CHF | 0,16CHF | 1,21% |
WKN DE: A3C317 / ISIN: CH1129677105
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 2 036 | 2 067 | 2 658 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,22 | 0,23 | 0,18 |
Bilanz (in Mio. CHF) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 187 | 155 | 340 | 489 | 308 |
| Summe Anlagevermögen | 515 | 640 | 644 | 625 | 707 |
| Summe Aktiva | 701 | 795 | 984 | 1 114 | 1 015 |
Bilanz (in Mio. CHF) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 406 | 461 | 450 | 610 | 541 |
| Summe Eigenkapital | 295 | 333 | 534 | 505 | 474 |
| Summe Passiva | 701 | 795 | 984 | 1 114 | 1 015 |
Adresse
| Neuhofstrasse 20, 6340 Zug | |
| Telefon | +41 (41) 723-73-00 |
| Internet | http://www.medmix.swiss |
Management
|
Alan Richardson
Chief Operations Officer |
|
Barbara Angehrn Pavik
Independent Non-Executive Director |
|
Daniel O. Flammer
Director |
|
David Metzger
Independent Non-Executive Director |
|
Holger Warth
Chief Technology & Innovation Officer |
|
Itee Satpathy
Chief Human Resources & Communication Officer |
|
James R. Amoroso
Head-Investor Relations |
|
Jennifer Dean
Chief Financial Officer |
|
Marco Musetti
Vice Chairman |
|
René Willi
Chief Executive Officer & Director |
|
Robert J. W. ten Hoedt
Independent Non-Executive Chairman |
|
Xavier Schops
Secretary & Chief Legal Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.